Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 01 2025
0mins
Should l Buy PAVM?
Source: NASDAQ.COM
BioAtla Inc. Gains: BioAtla's shares surged 13.94% in after-hours trading, attributed to investor reactions to recent financing agreements, despite no new company-specific news.
Metagenomi Inc. and PAVmed Inc. Movements: Metagenomi's stock rose 5.71% with no new updates, while PAVmed advanced 5.72% after reporting a significant net loss and a sharp decline in revenue.
Precision BioSciences' Positive Outlook: Precision BioSciences gained 2.94% after announcing it will present Phase 1 trial data at an upcoming conference, boosting investor optimism.
Entero Therapeutics Rebranding: Entero Therapeutics' shares increased 3.68% following its announcement of a rebranding to GridAI Technologies Corp., effective December 1, 2025, along with a new ticker symbol.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PAVM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PAVM
Wall Street analysts forecast PAVM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.120
Low
17.00
Averages
17.00
High
17.00
Current: 9.120
Low
17.00
Averages
17.00
High
17.00
About PAVM
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lucid Diagnostics CEO to Participate in Healthcare Conference
- Conference Participation: Lucid Diagnostics CEO Lishan Aklog, M.D. will participate in the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026, showcasing the company's leadership in cancer prevention, which is expected to attract attention from investors and the healthcare industry.
- Live Webcast: The event will be webcast live via the Investor Relations section of Lucid Diagnostics' website, providing broader audience reach, enhancing company transparency, and improving brand image.
- Cancer Prevention Technology: Lucid focuses on cancer prevention for patients with gastroesophageal reflux disease, with its EsoGuard® and EsoCheck® devices representing the first commercially available solutions for early detection of esophageal cancer, indicating significant market potential.
- Company Background: As a subsidiary of PAVmed Inc., Lucid Diagnostics is committed to improving patient health through innovative medical diagnostic technologies, demonstrating its strategic importance in the field of cancer prevention.
See More
PAVmed Appoints New Executive to Drive Medical Device Development
- Executive Appointment: PAVmed has appointed medical technology veteran Joseph Virgilio as Senior Vice President and Chief Business Officer for Medical Devices, tasked with overseeing the development and commercialization of the company's current and future medical device portfolio, aiming to enhance market competitiveness through experienced leadership.
- Capital Structure Optimization: By improving its capital structure and strengthening its balance sheet, PAVmed is poised to relaunch its medical device portfolio, which is expected to create long-term shareholder value and aligns with the company's strategic goal of diversified growth.
- Technology Portfolio Relaunch: Under Virgilio's leadership, PAVmed has relaunched its medical device portfolio, which includes the PortIO implantable intraosseous vascular access device and endoscopic imaging technology licensed from Duke University, aimed at improving the efficiency and effectiveness of medical services.
- Subsidiary Development: The newly formed subsidiary Octeris will focus on advancing endoscopic technology, with Virgilio serving as CEO for both PortIO and Octeris, driving collaborative research with Duke University to further expand the medical device market.
See More
PAVmed Reports Q4 2025 Earnings with Key Metrics
- Revenue and Test Volume Growth: PAVmed reported $1.5 million in revenue for Q4 2025, with EsoGuard test volume reaching 3,664, a 29% increase from Q3, indicating rising market demand in the medical testing sector, although overall financial health remains challenged.
- Net Loss and Operating Expenses: The company faced a GAAP net loss of $2.8 million in Q4, with a non-GAAP loss of $942,000, while operating expenses have remained nearly flat since Lucid's deconsolidation in 2024, reflecting efforts to control costs amidst ongoing financial pressures.
- Strategic Restructuring and Financing: PAVmed successfully completed a restructuring recapitalization, eliminating toxic convertible securities and achieving a clean capital structure, which lays a foundation for future business development and enhances financial stability.
- New Technologies and Market Expansion: PAVmed is relaunching its MedTech portfolio with a focus on innovative technologies, including an endoscopic imaging technology licensed from Duke University, which, despite being in early stages, holds potential for future growth through commercialization efforts.
See More
PAVmed Reports Q4 2025 Financial Results with Key Metrics
- Financial Performance: PAVmed reported a Q4 2025 non-GAAP EPS of -$1.05, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, PAVmed had cash and cash equivalents of $1.5 million, an increase from $1.2 million in the same period of 2024, suggesting improved cash management despite ongoing operational challenges.
- Operating Expenses: The company's operating expenses for Q4 2025 were approximately $6.9 million, which included $0.3 million in stock-based compensation, highlighting the financial pressures associated with ongoing operations and employee incentives.
- Reverse Stock Split: PAVmed announced a 1-for-30 reverse stock split, a strategic move aimed at increasing the share price to attract more investor interest, although it may impact liquidity in the short term.
See More
PAVmed Restructures Capital and Relaunches Product Line
- Capital Structure Optimization: Over the past two years, PAVmed has undertaken a series of systematic actions to repair its legacy capital structure, successfully strengthening its balance sheet, which is expected to lay a solid foundation for the company's future high growth.
- Strategic Partnership Progress: Veris Health is advancing its strategic partnership with Ohio State University into the commercial phase, while its implantable physiological monitor is progressing toward FDA submission, indicating ongoing innovation in personalized cancer care.
- Medical Device Portfolio Relaunch: PAVmed has relaunched its medical device product portfolio under new leadership and completed the licensing of its endoscopic esophageal imaging technology from Duke University, further enriching the company's growth engines.
- EsoGuard Coverage Expansion: Lucid Diagnostics is nearing transformative Medicare coverage, continuously expanding the accessibility and clinical evidence base of the EsoGuard healthcare system, which is expected to significantly enhance its market competitiveness.
See More
Lucid Diagnostics Reports Q4 Highlights and Revenue Growth
- Revenue Growth: Lucid Diagnostics reported $1.5 million in revenue for Q4 2025, a 25.5% increase from $1.197 million in 2024, indicating sustained market demand in cancer prevention.
- Contract Expansion: The company secured a contract with the U.S. Department of Veterans Affairs, enhancing EsoGuard's accessibility, which not only increases market penetration but also lays a foundation for future revenue growth.
- Strengthened Clinical Evidence: By presenting the largest reported real-world experience in esophageal precancer detection, Lucid has bolstered the clinical evidence for EsoGuard, which will help enhance trust among physicians and patients, thereby driving broader adoption of the product.
- Future Outlook: Lucid plans to deepen its relationship with the VA, expand adoption across health systems, and secure Medicare coverage in 2026, with these initiatives expected to further drive revenue growth.
See More
Lucid Diagnostics CEO to Participate in Healthcare Conference
- Conference Participation: Lucid Diagnostics CEO Lishan Aklog, M.D. will participate in the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026, showcasing the company's leadership in cancer prevention, which is expected to attract attention from investors and the healthcare industry.
- Live Webcast: The event will be webcast live via the Investor Relations section of Lucid Diagnostics' website, providing broader audience reach, enhancing company transparency, and improving brand image.
- Cancer Prevention Technology: Lucid focuses on cancer prevention for patients with gastroesophageal reflux disease, with its EsoGuard® and EsoCheck® devices representing the first commercially available solutions for early detection of esophageal cancer, indicating significant market potential.
- Company Background: As a subsidiary of PAVmed Inc., Lucid Diagnostics is committed to improving patient health through innovative medical diagnostic technologies, demonstrating its strategic importance in the field of cancer prevention.
See More
PAVmed Appoints New Executive to Drive Medical Device Development
- Executive Appointment: PAVmed has appointed medical technology veteran Joseph Virgilio as Senior Vice President and Chief Business Officer for Medical Devices, tasked with overseeing the development and commercialization of the company's current and future medical device portfolio, aiming to enhance market competitiveness through experienced leadership.
- Capital Structure Optimization: By improving its capital structure and strengthening its balance sheet, PAVmed is poised to relaunch its medical device portfolio, which is expected to create long-term shareholder value and aligns with the company's strategic goal of diversified growth.
- Technology Portfolio Relaunch: Under Virgilio's leadership, PAVmed has relaunched its medical device portfolio, which includes the PortIO implantable intraosseous vascular access device and endoscopic imaging technology licensed from Duke University, aimed at improving the efficiency and effectiveness of medical services.
- Subsidiary Development: The newly formed subsidiary Octeris will focus on advancing endoscopic technology, with Virgilio serving as CEO for both PortIO and Octeris, driving collaborative research with Duke University to further expand the medical device market.
See More
PAVmed Reports Q4 2025 Earnings with Key Metrics
- Revenue and Test Volume Growth: PAVmed reported $1.5 million in revenue for Q4 2025, with EsoGuard test volume reaching 3,664, a 29% increase from Q3, indicating rising market demand in the medical testing sector, although overall financial health remains challenged.
- Net Loss and Operating Expenses: The company faced a GAAP net loss of $2.8 million in Q4, with a non-GAAP loss of $942,000, while operating expenses have remained nearly flat since Lucid's deconsolidation in 2024, reflecting efforts to control costs amidst ongoing financial pressures.
- Strategic Restructuring and Financing: PAVmed successfully completed a restructuring recapitalization, eliminating toxic convertible securities and achieving a clean capital structure, which lays a foundation for future business development and enhances financial stability.
- New Technologies and Market Expansion: PAVmed is relaunching its MedTech portfolio with a focus on innovative technologies, including an endoscopic imaging technology licensed from Duke University, which, despite being in early stages, holds potential for future growth through commercialization efforts.
See More
PAVmed Reports Q4 2025 Financial Results with Key Metrics
- Financial Performance: PAVmed reported a Q4 2025 non-GAAP EPS of -$1.05, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, PAVmed had cash and cash equivalents of $1.5 million, an increase from $1.2 million in the same period of 2024, suggesting improved cash management despite ongoing operational challenges.
- Operating Expenses: The company's operating expenses for Q4 2025 were approximately $6.9 million, which included $0.3 million in stock-based compensation, highlighting the financial pressures associated with ongoing operations and employee incentives.
- Reverse Stock Split: PAVmed announced a 1-for-30 reverse stock split, a strategic move aimed at increasing the share price to attract more investor interest, although it may impact liquidity in the short term.
See More
PAVmed Restructures Capital and Relaunches Product Line
- Capital Structure Optimization: Over the past two years, PAVmed has undertaken a series of systematic actions to repair its legacy capital structure, successfully strengthening its balance sheet, which is expected to lay a solid foundation for the company's future high growth.
- Strategic Partnership Progress: Veris Health is advancing its strategic partnership with Ohio State University into the commercial phase, while its implantable physiological monitor is progressing toward FDA submission, indicating ongoing innovation in personalized cancer care.
- Medical Device Portfolio Relaunch: PAVmed has relaunched its medical device product portfolio under new leadership and completed the licensing of its endoscopic esophageal imaging technology from Duke University, further enriching the company's growth engines.
- EsoGuard Coverage Expansion: Lucid Diagnostics is nearing transformative Medicare coverage, continuously expanding the accessibility and clinical evidence base of the EsoGuard healthcare system, which is expected to significantly enhance its market competitiveness.
See More
Lucid Diagnostics Reports Q4 Highlights and Revenue Growth
- Revenue Growth: Lucid Diagnostics reported $1.5 million in revenue for Q4 2025, a 25.5% increase from $1.197 million in 2024, indicating sustained market demand in cancer prevention.
- Contract Expansion: The company secured a contract with the U.S. Department of Veterans Affairs, enhancing EsoGuard's accessibility, which not only increases market penetration but also lays a foundation for future revenue growth.
- Strengthened Clinical Evidence: By presenting the largest reported real-world experience in esophageal precancer detection, Lucid has bolstered the clinical evidence for EsoGuard, which will help enhance trust among physicians and patients, thereby driving broader adoption of the product.
- Future Outlook: Lucid plans to deepen its relationship with the VA, expand adoption across health systems, and secure Medicare coverage in 2026, with these initiatives expected to further drive revenue growth.
See More
